ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

Only approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapy Launch expands AstraZeneca’s commitment to addressing substantial unmet need across the spectrum of